AU2022407440A1 - Solid state forms of an fgfr inhibitor - Google Patents

Solid state forms of an fgfr inhibitor Download PDF

Info

Publication number
AU2022407440A1
AU2022407440A1 AU2022407440A AU2022407440A AU2022407440A1 AU 2022407440 A1 AU2022407440 A1 AU 2022407440A1 AU 2022407440 A AU2022407440 A AU 2022407440A AU 2022407440 A AU2022407440 A AU 2022407440A AU 2022407440 A1 AU2022407440 A1 AU 2022407440A1
Authority
AU
Australia
Prior art keywords
solid form
exhibits
ray powder
powder diffraction
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022407440A
Other languages
English (en)
Inventor
Shubham Chopade
Jason M. Cox
Stephen W. Kaldor
Robert Kania
Toufike Kanouni
Preetanshu Pandey
Andrew PHIMISTER
Jayachandra P. REDDY
John Tyhonas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kinnate Biopharma Inc
Original Assignee
Kinnate Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kinnate Biopharma Inc filed Critical Kinnate Biopharma Inc
Publication of AU2022407440A1 publication Critical patent/AU2022407440A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
AU2022407440A 2021-12-08 2022-12-07 Solid state forms of an fgfr inhibitor Pending AU2022407440A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163287212P 2021-12-08 2021-12-08
US63/287,212 2021-12-08
PCT/US2022/081060 WO2023107980A1 (en) 2021-12-08 2022-12-07 Solid state forms of an fgfr inhibitor

Publications (1)

Publication Number Publication Date
AU2022407440A1 true AU2022407440A1 (en) 2024-06-20

Family

ID=86731361

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022407440A Pending AU2022407440A1 (en) 2021-12-08 2022-12-07 Solid state forms of an fgfr inhibitor

Country Status (12)

Country Link
US (1) US20250059170A1 (https=)
EP (1) EP4444302A4 (https=)
JP (1) JP2024542840A (https=)
KR (1) KR20240119095A (https=)
CN (1) CN118804748A (https=)
AU (1) AU2022407440A1 (https=)
CA (1) CA3239792A1 (https=)
CL (1) CL2024001679A1 (https=)
IL (1) IL313359A (https=)
MX (1) MX2024006933A (https=)
TW (1) TW202332432A (https=)
WO (1) WO2023107980A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11345681B1 (en) 2020-06-05 2022-05-31 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
AU2022407439A1 (en) * 2021-12-08 2024-06-27 Kinnate Biopharma Inc. Treatment of cancer with an fgfr kinase inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10124003B2 (en) * 2013-07-18 2018-11-13 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for FGFR inhibitor-resistant cancer
CN107840842A (zh) * 2016-09-19 2018-03-27 北京天诚医药科技有限公司 炔代杂环化合物、其制备方法及其在医药学上的应用
EP3969442A4 (en) * 2019-05-17 2023-08-02 Kinnate Biopharma Inc. FIBROBLAST GROWTH FACTOR RECEPTOR KINASE INHIBITORS
US11345681B1 (en) * 2020-06-05 2022-05-31 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases

Also Published As

Publication number Publication date
TW202332432A (zh) 2023-08-16
IL313359A (en) 2024-08-01
KR20240119095A (ko) 2024-08-06
EP4444302A1 (en) 2024-10-16
WO2023107980A1 (en) 2023-06-15
CA3239792A1 (en) 2023-06-15
CL2024001679A1 (es) 2024-11-29
US20250059170A1 (en) 2025-02-20
CN118804748A (zh) 2024-10-18
EP4444302A4 (en) 2025-09-03
MX2024006933A (es) 2024-08-26
JP2024542840A (ja) 2024-11-15

Similar Documents

Publication Publication Date Title
US11123338B2 (en) C-met modulator pharmaceutical compositions
TW201524507A (zh) 雜環化合物及其用途
JP7825636B2 (ja) （ｓ）－ｎ－（３－（２－（（（ｒ）－１－ヒドロキシプロパン－２－イル）アミノ）－６－モルホリノピリジン－４－イル）－４－メチルフェニル）－３－（２，２，２－トリフルオロエチル）ピロリジン－１－カルボキサミドおよびその塩の固体状態での形態
US20250059170A1 (en) Solid state forms of an fgfr inhibitor
CN106279126B (zh) 阿法替尼酸加成盐及其晶型、其制备方法及药物组合物
TWI922665B (zh) (s)-n-(3-(2-(((r)-1-羥基丙-2-基)胺基)-6-嗎啉基吡啶-4-基)-4-甲基苯基)-3-(2,2,2-三氟乙基)吡咯啶-1-甲醯胺及其鹽之固態形式
US20240270733A1 (en) Hydrate form of lazertinib mesylate, preparation method thereof and use thereof
CN102666528A (zh) 晶体cdc7 抑制剂盐
WO2025207649A1 (en) Solid state forms of an akt1 inhibitor and salts thereof
HK40107041A (zh) 固态形式的(s)-n-(3-(2-(((r)-1-羟基丙-2-基)氨基)-6-吗啉代吡啶-4-基)-4-甲基苯基)-3-(2，2，2-三氟乙基)吡咯烷-1-甲酰胺及其盐
HK1185553B (en) C-met modulator pharmaceutical compositions